Biocryst Pharma Inc (BCRX) Stock Price, Quote & News

Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phas...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 919 859 1302

Fax: 919 859 1314

Website: www.biocryst.com

Address:

4505 Emperor Boulevard, Suite 200, Durham, United States

Irun3 Feb. 23 at 10:54 PM

$BCRX New job posting.

1 · Reply

SCCT2FL Feb. 23 at 9:20 PM

$BCRX there's no bump in call prices as the share price rises? 3/20 $7 calls, bid is at $0.70 as the share price is at 7.58. That's 12 cents, everyone must think this will drop at some point

1 · Reply

Fergus20 Feb. 23 at 9:01 PM

$BCRX I don’t believe this

1 · Reply

pocketmoney Feb. 23 at 8:55 PM

$BCRX Evercore $17 PT 🙄

0 · Reply

Paulzk Feb. 23 at 8:40 PM

$BCRX Rates dropping predicting a slower economy and more layoffs CBOE Interest Rate 10 Year T No (^TNX) 4.0290 -0.0570 (-1.39%)

0 · Reply

Paulzk Feb. 23 at 8:39 PM

$BCRX The Bitcoin crash continues 64,187.53 -3,198.02 (-4.75%)

0 · Reply

Paulzk Feb. 23 at 8:38 PM

$BCRX Big move by gold today 5,228.6 +121.92 +2.39%

0 · Reply

ktrader1991 Feb. 23 at 8:07 PM

$BCRX I believe they will or should raise guidance for 2026 based on the last 6-8 weeks of sales for 2026.

1 · Reply

Astronave Feb. 23 at 7:54 PM

$BCRX At this rate we'll get to 8 next year.

0 · Reply

Del_Gue Feb. 23 at 7:24 PM

$BCRX So what’s up with our rising price on lower than normal volume? Seems to be the case with our recent climb out of the toilet. Anyone have thoughts on this?

1 · Reply

BioCryst to Present at Upcoming Investor Conference

Feb 11, 2026, 7:00 AM EST - 12 days ago

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

Feb 5, 2026, 7:01 AM EST - 18 days ago

BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

Feb 5, 2026, 7:00 AM EST - 18 days ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 23, 2026, 9:00 AM EST - 4 weeks ago

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

Jan 12, 2026, 3:56 PM EST - 6 weeks ago

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:00 AM EST - 6 weeks ago

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

Jan 6, 2026, 7:00 AM EST - 6 weeks ago

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 12, 2025, 7:06 AM EST - 2 months ago

FDA expands approval of BioCryst's rare disease drug for use in young children

Dec 12, 2025, 7:00 AM EST - 2 months ago

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to

Dec 3, 2025, 7:00 AM EST - 2 months ago

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

Nov 24, 2025, 2:23 PM EST - 3 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 6, 2025, 8:00 AM EST - 3 months ago

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

Nov 3, 2025, 12:16 PM EST - 4 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 7:00 AM EST - 4 months ago

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 23, 2025, 7:00 AM EDT - 4 months ago

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

Oct 20, 2025, 7:00 AM EDT - 4 months ago

BioCryst to Report Third Quarter 2025 Financial Results on November 3

Oct 17, 2025, 3:20 PM EDT - 4 months ago

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

ATXS

Oct 14, 2025, 1:16 PM EDT - 4 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript

Oct 14, 2025, 12:20 PM EDT - 4 months ago

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

ATXS

Oct 14, 2025, 7:35 AM EDT - 4 months ago

BioCryst to buy Astria Therapeutics in $700 million deal

ATXS

Oct 14, 2025, 7:00 AM EDT - 4 months ago

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

ATXS

Oct 1, 2025, 7:00 AM EDT - 5 months ago

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

Sep 29, 2025, 2:53 AM EDT - 5 months ago

BioCryst: Blue Light Special In Small Cap Biotech Aisle

Sep 5, 2025, 5:47 AM EDT - 6 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Aug 11, 2025, 7:00 AM EDT - 7 months ago

BioCryst Announces Departure of Dr. Helen Thackray

Aug 4, 2025, 11:38 AM EDT - 7 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 7:00 AM EDT - 7 months ago

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:00 AM EDT - 7 months ago

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

Jul 21, 2025, 7:00 AM EDT - 7 months ago

BioCryst to Report Second Quarter 2025 Financial Results on August 4

Jul 9, 2025, 7:00 AM EDT - 8 months ago

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

Jul 7, 2025, 7:00 AM EDT - 8 months ago

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

Jun 27, 2025, 7:00 AM EDT - 8 months ago

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Jun 16, 2025, 7:00 AM EDT - 9 months ago

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

Jun 13, 2025, 7:00 AM EDT - 9 months ago

ORLADEYO® (berotralstat) Approved in Colombia

Jun 6, 2025, 7:00 AM EDT - 9 months ago

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

Jun 2, 2025, 7:00 AM EDT - 9 months ago

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

May 30, 2025, 7:00 AM EDT - 9 months ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

May 27, 2025, 7:00 AM EDT - 9 months ago

BioCryst to Present at Upcoming Investor Conferences

May 16, 2025, 7:00 AM EDT - 10 months ago

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

May 14, 2025, 7:00 AM EDT - 10 months ago

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

May 5, 2025, 5:29 PM EDT - 10 months ago

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

May 5, 2025, 2:05 PM EDT - 10 months ago

BioCryst: Strong Opportunity For A Double With A Proven Therapy

May 5, 2025, 12:54 PM EDT - 10 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 7:00 AM EDT - 10 months ago

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 7:00 AM EDT - 10 months ago

BioCryst Appoints Steve Frank to Board of Directors

Apr 21, 2025, 7:00 AM EDT - 11 months ago

BioCryst to Report First Quarter 2025 Financial Results on May 5

Feb 26, 2025, 9:09 AM EST - 1 year ago

BioCryst: Orladeyo's Expansion Is Just Getting Started

Feb 26, 2025, 7:45 AM EST - 1 year ago

BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up

Irun3 Feb. 23 at 10:54 PM

$BCRX New job posting.

1 · Reply

SCCT2FL Feb. 23 at 9:20 PM

$BCRX there's no bump in call prices as the share price rises? 3/20 $7 calls, bid is at $0.70 as the share price is at 7.58. That's 12 cents, everyone must think this will drop at some point

1 · Reply

Fergus20 Feb. 23 at 9:01 PM

$BCRX I don’t believe this

1 · Reply

pocketmoney Feb. 23 at 8:55 PM

$BCRX Evercore $17 PT 🙄

0 · Reply

Paulzk Feb. 23 at 8:40 PM

$BCRX Rates dropping predicting a slower economy and more layoffs CBOE Interest Rate 10 Year T No (^TNX) 4.0290 -0.0570 (-1.39%)

0 · Reply

Paulzk Feb. 23 at 8:39 PM

$BCRX The Bitcoin crash continues 64,187.53 -3,198.02 (-4.75%)

0 · Reply

Paulzk Feb. 23 at 8:38 PM

$BCRX Big move by gold today 5,228.6 +121.92 +2.39%

0 · Reply

ktrader1991 Feb. 23 at 8:07 PM

$BCRX I believe they will or should raise guidance for 2026 based on the last 6-8 weeks of sales for 2026.

1 · Reply

Astronave Feb. 23 at 7:54 PM

$BCRX At this rate we'll get to 8 next year.

0 · Reply

Del_Gue Feb. 23 at 7:24 PM

$BCRX So what’s up with our rising price on lower than normal volume? Seems to be the case with our recent climb out of the toilet. Anyone have thoughts on this?

1 · Reply

strongterrence Feb. 23 at 6:54 PM

$BCRX my bet is earnings will beat and insiders are covering short positions as we speak, 12% up or down on thursday either way the Mac D is positive the trend is my friend until it isn't so 21k shares will ride on through earnings

2 · Reply

BirdStar Feb. 23 at 6:16 PM

$BCRX Fly, Moth, Fly!😁

0 · Reply

Paulzk Feb. 23 at 4:06 PM

$BCRX Dow Jones Industrial Average 48,845.58 -780.39 (-1.57%)

0 · Reply

Paulzk Feb. 23 at 4:04 PM

$BCRX Shit -301.23

0 · Reply

Paulzk Feb. 23 at 4:03 PM

$BCRX Thank you Donald company logo NASDAQ COMPOSITE INDEX COMP 22,593.88 -292.193 (-1.28%)

0 · Reply

Paulzk Feb. 23 at 4:00 PM

$BCRX I guess the market does not like Trump trade war 2.0

0 · Reply

DragonAlgo Feb. 23 at 3:08 PM

🐉 $BCRX CALL — DragonAlgo® Signal Contract: BCRX CALL Expiry: 2026-03-20 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 Risk preset by model constraints. 🔗 https://dragonalgo.com

0 · Reply

Saffier1988 Feb. 23 at 3:04 PM

$BCRX glitch????

1 · Reply

Del_Gue Feb. 23 at 2:38 PM

$BCRX @YerbMe

0 · Reply

BirdStar Feb. 23 at 2:32 PM

$BCRX

1 · Reply

Fergus20 Feb. 23 at 2:11 PM

$BCRX let’s go

0 · Reply

Paulzk Feb. 23 at 9:21 AM

$BCRX https://www.schwab.com/learn/story/529-to-roth-ira-rollovers-what-to-know

0 · Reply

Market Cap	1.57B
Revenue (ttm)	450.71M
Net Income (ttm)	-88.88M
EPS (ttm)	N/A
PE Ratio	93.50
Forward PE	25.62
Profit Margin	-19.72%
Debt to Equity Ratio	-1.73

Volume	2,626,666
Avg Vol	4,142,770
Day's Range	N/A - N/A
Shares Out	210.74M
Stochastic %K	96%
Beta	0.83
Analysts	Strong Sell
Price Target	$20.09